[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-lobular-breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-lobular-breast-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100594542","phase-1-68gaga-dota-5g-as-a-diagnostic-imaging-agent-for-metastaticadvanced-invasive-lobular-breast-cancer-lbc-100594542",false,"NCT07020806","[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic\u002FAdvanced Invasive Lobular Breast Cancer (LBC)","Inclusion Criteria:\n\n* (Ability to understand and willingness to sign a written informed consent document.\n* Men and women age ≥ 18 yrs\n* Confirmed presence of metastatic\u002Fadvanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST\n* Available archival tumor tissue\n* Eastern Cooperative Oncology Group Performance Status ≤ 2\n* Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells\u002Fmm3,Platelet count ≥ 100,000\u002Fmm3, Hemoglobin ≥ 8 g\u002FdL.\n* Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \\>60 mL\u002Fmin\u002F1.73m\\*2\n* Anticipated life expectancy ≥ 3 months\n* Able to remain motionless for up to 30-60 minutes per scan.\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Prisoners\n* Concurrent malignancy of a different histology that could confound imaging interpretation.\n* Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)","ALL","18 Years","89 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a prospective study using \\[68Ga\\]Ga DOTA-5G PET\u002FCT imaging in patients diagnosed with metastatic\u002Fadvanced invasive lobular breast cancer (LBC).",[26],"Metastatic Lobular Breast Carcinoma","RECRUITING","2026-03-19",{"date":30,"type":31},"2026-03-23","ACTUAL",{"date":33,"type":31},"2025-11-18",{"date":35,"type":20},"2027-06",{"name":37,"class":38},"University of California, Davis","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100558901","a-study-comparing-cancer-imaging-approaches-in-people-with-lobular-breast-cancer-100558901","NCT06557148","A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer","18F-Fluoroestradiol (FES) Positron Emission Tomography for the Detection and Treatment Response Monitoring in Patients With Metastatic Lobular Breast Carcinoma","Inclusion Criteria:\n\n* Adult patient \\> 18 years old\n* Biopsy-proven metastatic ILC\n* Confirmed ER+ breast cancer from either primary tumor or metastatic biopsy (ER receptor percent staining ≥ 10% of tumor cells by IHC)\n* HER2-negative per ASCO\u002FCAP\n* ECOG Performance Status Score of 0, 1 or 2.\n* Patient can have received up to 2 lines of therapy in the metastatic setting\n* Life expectancy of at least 12 months\n\nExclusion Criteria:\n\n* Low ER expression defined as ER \\\u003C10% of tumor cells by IHC\n* Patients who have been on adjuvant ER-blocking endocrine therapy with SERM or SERD without an 8- and 24-weeks washout, respectively. (The use of aromatase inhibitors or ovarian suppression is permitted given that they do not block estrogen receptors).\n* Pregnancy or lactation or parturient or nursing mother\n* Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and\u002For who has a life expectancy of \\\u003C12 months, or for whom study participation may compromise their management; and\u002For a patient who the investigator judges to be unsuitable for participation in the study for any reason.",{"count":19,"type":20},"OBSERVATIONAL","The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET\u002FCT (positron emission tomography\u002Fcomputed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET\u002FCT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET\u002FCT scans and FDG PET\u002FCT scans.",[51,52,53,54,26,55],"Breast Cancer","Lobular Breast Carcinoma","Breast Carcinoma","Metastatic Breast Cancer","Metastatic Breast Carcinoma",[57,58,59,60,61,62,63,64,65,66],"breast cancer","lobular breast cancer","lobular breast carcinoma","breast carcinoma","metastatic breast cancer","metastatic lobular breast cancer","metastatic lobular breast carcinoma","metastatic breast carcinoma","24-134","Memorial Sloan Kettering Cancer Center","2026-02-25",{"date":69,"type":31},"2026-02-27",{"date":71,"type":31},"2024-08-13",{"date":73,"type":20},"2027-08-13",{"name":66,"class":38},7]